Attention: This platform is in beta mode. Expect some changes and adjustments.

AI Market Mood: Stock Dashboard

PRME


Fundamental

Company: Prime Medicine Inc
Sector: Healthcare
Industry: Biotechnology
Country: USA
Exchange: NASD
Index: RUT
P/E: -
EPS (ttm): -1.48
Insider Own: 48.57%
Shs Outstand: 180.31M
Perf Week: -22.70%
Market Cap: 628.14M
Forward P/E: -
EPS next Y: -0.91
Insider Trans: 14.44%
Shs Float: 91.65M
Perf Month: -37.94%
Enterprise Value: 532.99M
PEG: -
EPS next Q: -0.23
Inst Own: 24.34%
Short Float: 17.21%
Perf Quarter: 1.88%
Income: -197.34M
P/S: 105.04
EPS this Y: 23.81%
Inst Trans: 3.49%
Short Ratio: 4.31
Perf Half Y: 163.06%
Sales: 5.98M
P/B: 3.93
EPS next Y Percentage: 27.91%
ROA: -54.98%
Short Interest: 15.77M
Perf YTD: 20.72%
Book/sh: 0.90
P/C: 2.95
EPS next 5Y: 19.94%
ROE: -112.34%
52W High: 6.94 -49.21%
Perf Year: -14.02%
Cash/sh: 1.20
P/FCF: -
EPS past 3/5Y: 4.95% -124.13%
ROIC: -72.49%
52W Low: 1.11 217.57%
Perf 3Y: -81.09%
Dividend Est.: -
EV/EBITDA: -
Sales past 3/5Y: - -
Gross Margin: -19.83%
Volatility W: 10.41%
Volatility M: 10.59%
Perf 5Y: -
Dividend TTM: -
EV/Sales: 89.13
EPS Y/Y TTM: 24.90%
Oper. Margin: -3412.48%
ATR (14): 0.50
Perf 10Y: -
Dividend Ex-Date: -
Quick Ratio: 6.61
Sales Y/Y TTM: 647.12%
Profit Margin: -3301.64%
RSI (14): 34.05
Recom: 1.60
Dividend Gr. 3/5Y: - -
Current Ratio: 6.61
EPS Q/Q: 28.12%
SMA20: -29.34%
Beta: 2.74
Target Price: 6.57
Payout: -
Debt/Eq: 0.73
Sales Q/Q: 486.12%
SMA50: -29.05%
Rel Volume: 1.28
Prev Close: 3.81
Employees: 214
LT Debt/Eq: 0.68
Earnings: Nov 07 BMO
SMA200: 14.20%
Avg Volume: 3.66M
Price: 3.53
IPO: Oct 20, 2022
Option/Short: Yes / Yes
EPS/Sales Surpr.: -26.53% -52.54%
Trades:
Volume: 4,676,441
Change: -7.48%

Technical:


Latest News:

Citigroup Upgrades Prime Medicine (PRME) - Nasdaq very bullish
PRME

Summary: Citigroup upgraded their outlook for Prime Medicine from Neutral to Buy with an analyst price forecast suggesting 114.11% upside. Various funds and institutions have reported positions in Prime Medicine, totaling 70,064K shares, with a bullish outlook indicated by the put/call ratio of 0.12.

Full article
2024-05-17T22:16:55Z